Objective: To evaluate the insulin-only configuration of the iLet® bionic pancreas (BP) using fast-acting insulin aspart (Fiasp®) in adults with type 1 diabetes (T1D). Research Design and Methods: In this multicenter, randomized trial, 275 adults with T1D (18-83 years old, baseline HbA1c 5.3%-14.9%) were randomly assigned 2:2:1 to use the BP with fast-acting insulin aspart (BP-F group, N = 114), BP with aspart or lispro (BP-A/L group, N = 107), or a control group using their standard-care insulin delivery (SC group, N = 54) plus real-time continuous glucose monitoring (CGM). The primary outcome was HbA1c at 13 weeks. The BP-F versus SC comparison was considered primary and BP-F versus BP-A/L secondary. Results: Mean ± standard deviation (SD) HbA1c decreased from 7.8% ± 1.2% at baseline to 7.1% ± 0.6% at 13 weeks with BP-F versus 7.6% ± 1.2% to 7.5% ± 0.9% with SC (adjusted difference = -0.5%, 95% CI -0.7 to -0.3, P < 0.001). CGM-measured percent time <54 mg/dL over 13 weeks with BP-F was noninferior to SC (adjusted difference = 0.00%, 95% CI -0.07 to 0.05, P < 0.001 for noninferiority based on a prespecified noninferiority limit of 1%). Over 13 weeks, mean time in range 70-180 mg/dL (TIR) increased by 14% (3.4 h/day) and mean CGM glucose was reduced by 18 mg/dL with BP-F compared with SC (P < 0.001). Analyses of time >180 mg/dL, time >250 mg/dL, and the SD of CGM glucose all favored BP-F compared with SC (P < 0.001). Differences between BP-F and BP-A/L were minimal, with no difference in HbA1c at 13 weeks (adjusted difference = -0.0%, 95% CI -0.2 to 0.1, P = 0.67) or mean glucose (adjusted difference = -2.0 mg/dL, 95% CI -4.3 to 0.4, P = 0.10). Mean TIR was 2% greater with BP-F than BP-A/L (95% CI 1 to 4, P = 0.005), but the percentages of participants improving TIR by ≥5% were not significantly different (P = 0.49) and there were no significant differences comparing BP-F versus BP-A/L across nine patient-reported outcome surveys. The rate of severe hypoglycemia events did not differ among the three groups. Conclusions: In adults with T1D, HbA1c was improved with the BP using fast-acting insulin aspart compared with standard care without increasing CGM-measured hypoglycemia. However, the effect was no better than the reduction observed with the BP using aspart or lispro. Clinical Trial Registry: clinicaltrials.gov; NCT04200313.
Objective: To evaluate the insulin-only configuration of the iLet® bionic pancreas (BP) using fast-acting insulin aspart (Fiasp®) in adults with type 1 diabetes (T1D). Research Design and Methods: In this multicenter, randomized trial, 275 adults with T1D (18-83 years old, baseline HbA1c 5.3%-14.9%) were randomly assigned 2:2:1 to use the BP with fast-acting insulin aspart (BP-F group, N = 114), BP with aspart or lispro (BP-A/L group, N = 107), or a control group using their standard-care insulin delivery (SC group, N = 54) plus real-time continuous glucose monitoring (CGM). The primary outcome was HbA1c at 13 weeks. The BP-F versus SC comparison was considered primary and BP-F versus BP-A/L secondary. Results: Mean ± standard deviation (SD) HbA1c decreased from 7.8% ± 1.2% at baseline to 7.1% ± 0.6% at 13 weeks with BP-F versus 7.6% ± 1.2% to 7.5% ± 0.9% with SC (adjusted difference = -0.5%, 95% CI -0.7 to -0.3, P < 0.001). CGM-measured percent time <54 mg/dL over 13 weeks with BP-F was noninferior to SC (adjusted difference = 0.00%, 95% CI -0.07 to 0.05, P < 0.001 for noninferiority based on a prespecified noninferiority limit of 1%). Over 13 weeks, mean time in range 70-180 mg/dL (TIR) increased by 14% (3.4 h/day) and mean CGM glucose was reduced by 18 mg/dL with BP-F compared with SC (P < 0.001). Analyses of time >180 mg/dL, time >250 mg/dL, and the SD of CGM glucose all favored BP-F compared with SC (P < 0.001). Differences between BP-F and BP-A/L were minimal, with no difference in HbA1c at 13 weeks (adjusted difference = -0.0%, 95% CI -0.2 to 0.1, P = 0.67) or mean glucose (adjusted difference = -2.0 mg/dL, 95% CI -4.3 to 0.4, P = 0.10). Mean TIR was 2% greater with BP-F than BP-A/L (95% CI 1 to 4, P = 0.005), but the percentages of participants improving TIR by ≥5% were not significantly different (P = 0.49) and there were no significant differences comparing BP-F versus BP-A/L across nine patient-reported outcome surveys. The rate of severe hypoglycemia events did not differ among the three groups. Conclusions: In adults with T1D, HbA1c was improved with the BP using fast-acting insulin aspart compared with standard care without increasing CGM-measured hypoglycemia. However, the effect was no better than the reduction observed with the BP using aspart or lispro. Clinical Trial Registry: clinicaltrials.gov; NCT04200313.
Authors: Parul J Patel; Kari Benasi; Gina Ferrari; Mark G Evans; Satya Shanmugham; Darrell M Wilson; Bruce A Buckingham Journal: Diabetes Technol Ther Date: 2013-10-03 Impact factor: 6.118
Authors: Richard M Bergenstal; Satish Garg; Stuart A Weinzimer; Bruce A Buckingham; Bruce W Bode; William V Tamborlane; Francine R Kaufman Journal: JAMA Date: 2016-10-04 Impact factor: 56.272
Authors: Sybil A McAuley; Melissa H Lee; Barbora Paldus; Sara Vogrin; Martin I de Bock; Mary B Abraham; Leon A Bach; Morton G Burt; Neale D Cohen; Peter G Colman; Elizabeth A Davis; Christel Hendrieckx; D Jane Holmes-Walker; Joey Kaye; Anthony C Keech; Kavita Kumareswaran; Richard J MacIsaac; Roland W McCallum; Catriona M Sims; Jane Speight; Stephen N Stranks; Vijaya Sundararajan; Steven Trawley; Glenn M Ward; Alicia J Jenkins; Timothy W Jones; David N O'Neal Journal: Diabetes Care Date: 2020-10-14 Impact factor: 19.112
Authors: Marc D Breton; Lauren G Kanapka; Roy W Beck; Laya Ekhlaspour; Gregory P Forlenza; Eda Cengiz; Melissa Schoelwer; Katrina J Ruedy; Emily Jost; Lori Carria; Emma Emory; Liana J Hsu; Mary Oliveri; Craig C Kollman; Betsy B Dokken; Stuart A Weinzimer; Mark D DeBoer; Bruce A Buckingham; Daniel Cherñavvsky; R Paul Wadwa Journal: N Engl J Med Date: 2020-08-27 Impact factor: 91.245
Authors: Anders L Carlson; Jennifer L Sherr; Dorothy I Shulman; Satish K Garg; Rodica Pop-Busui; Bruce W Bode; David R Lilenquist; Ron L Brazg; Kevin B Kaiserman; Mark S Kipnes; James R Thrasher; John H Chip Reed; Robert H Slover; Athena Philis-Tsimikas; Mark Christiansen; Benyamin Grosman; Anirban Roy; Melissa Vella; Richard A M Jonkers; Xiaoxiao Chen; John Shin; Toni L Cordero; Scott W Lee; Andrew S Rhinehart; Robert A Vigersky Journal: Diabetes Technol Ther Date: 2021-11-16 Impact factor: 6.118
Authors: Jane Lynch; Lauren G Kanapka; Steven J Russell; Edward R Damiano; Firas H El-Khatib; Katrina J Ruedy; Courtney Balliro; Peter Calhoun; Roy W Beck Journal: Diabetes Technol Ther Date: 2022-10 Impact factor: 7.337